Acura Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. We have discovered and developed three proprietary technology platforms to address abuse and misuse across multiple fronts. • Limitx™ Technology is designed to retard the release of active drug ingredients when an excess number of tablets are ingested. In 2014, we were awarded a $300,000 grant from the National Institute on Drug Abuse to advance early stage development of our Limitx Technology. • Aversion® Technology is a patented composition of commonly used active and inactive pharmaceutical ingredients providing abuse deterrent features to discourage common methods of pharmaceutical product misuse and abuse while providing effective pain relief. OXAYDO® Tablets (oxycodone HCl, CII), is the first approved product using Aversion® in the United States. On January 7, 2015, we entered into a Collaboration and License Agreement with Egalet US, Inc. granting to Egalet exclusive worldwide rights to manufacture and commercialize OXAYDO. OXAYDO is approved by the U.S. Food and Drug Administration for marketing in the United States in 5mg and 7.5mg strengths. Egalet launched OXAYDO in the United States late in the third quarter of 2015. • Impede® Technology is a combination of inactive ingredients that prevent the extraction or disrupt the direct conversion of pseudoephedrine from commonly used decongestant tablets into methamphetamine. NEXAFED® Decongestant with Impede Technology was launched into the United States market in December 2012 followed by NEXAFED Sinus Pressure + Pain in February 2015. We have multiple pseudoephedrine products in development utilizing Impede Technology.